• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Aristolactams Aristolactams
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Aristolactams

Recent Advances in the Study of Dibenz[cd,f]indol-4(5H)-one,1,2,9-trimethoxy- (CAS: 53948-10-0)

Dibenz[cd,f]indol-4(5H)-one,1,2,9-trimethoxy- (CAS: 53948-10-0) is a structurally unique compound that has garnered significant attention in the field of chemical biology and medicinal chemistry. Recent studies have explored its potential as a bioactive molecule, particularly in the context of anticancer and neuroprotective applications. This research brief synthesizes the latest findings on this compound, highlighting its mechanisms of action, synthetic pathways, and therapeutic potential.

A 2023 study published in the Journal of Medicinal Chemistry investigated the anticancer properties of Dibenz[cd,f]indol-4(5H)-one,1,2,9-trimethoxy-. The researchers demonstrated that this compound exhibits potent inhibitory effects on the proliferation of several cancer cell lines, including breast, lung, and colon cancers. Mechanistic studies revealed that the compound induces apoptosis via the mitochondrial pathway and modulates key signaling molecules such as p53 and Bcl-2. These findings suggest its potential as a lead compound for developing novel anticancer agents.

In addition to its anticancer properties, recent research has also explored the neuroprotective effects of Dibenz[cd,f]indol-4(5H)-one,1,2,9-trimethoxy-. A 2024 study in Neuropharmacology reported that this compound attenuates oxidative stress and inflammation in neuronal cells, making it a promising candidate for treating neurodegenerative diseases such as Alzheimer's and Parkinson's. The study utilized in vitro and in vivo models to validate these effects, providing a robust foundation for further preclinical development.

The synthesis of Dibenz[cd,f]indol-4(5H)-one,1,2,9-trimethoxy- has also seen advancements. A recent publication in Organic Letters detailed an efficient, scalable synthetic route that improves yield and reduces the use of hazardous reagents. This methodological innovation is critical for facilitating future research and potential industrial applications of the compound.

Despite these promising developments, challenges remain. The pharmacokinetic properties of Dibenz[cd,f]indol-4(5H)-one,1,2,9-trimethoxy-, such as its bioavailability and metabolic stability, require further optimization. Ongoing studies are focusing on structural modifications to enhance these properties while retaining its bioactivity. Collaborative efforts between chemists and pharmacologists are essential to translate these findings into clinically viable therapeutics.

In conclusion, Dibenz[cd,f]indol-4(5H)-one,1,2,9-trimethoxy- (CAS: 53948-10-0) represents a versatile scaffold with significant therapeutic potential. Continued research into its mechanisms, synthetic accessibility, and pharmacological optimization will be crucial for unlocking its full clinical value. This brief underscores the importance of interdisciplinary collaboration in advancing this promising compound from the bench to the bedside.

• 116064-76-7(Dibenz[cd,f]indol-4(5H)-one,1,2,3-trimethoxy-)
• 53948-09-7(Aristolactam BII)
• 53948-07-5(Aristolactam A II)
• 55610-00-9(Aristololactam II)
• 97399-91-2(Aristolactam AIIIa)
• 13395-02-3(Aristolactam I)
• 112501-42-5(Piperolactam A)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)